FDA: Page 80
-
Two for two: FDA panel gives green light to Novartis' Enbrel biosim
Earlier this week the same committee had supported approval of Amgen's biosimilar of Humira.
By Nicole Gray • July 14, 2016 -
Amgen touts new dosing option for underperforming cholesterol drug
Repatha is competing with Sanofi and Regeneron's rival PCSK9 drug Praluent.
By Nicole Gray • July 13, 2016 -
FDA approves broader use of Pfizer's pneumonia vaccine
Prevnar is now approved for use in adults between the ages of 18 and 49.
By Nicole Gray • July 13, 2016 -
FDA
FDA panel unanimously recommends approval of Amgen's Humira biosimilar
But Amgen's win is tempered by the biosimilar threat to its own blockbuster biologic Enbrel, with a copy made by Novartis under review today.
By Nicole Gray • July 13, 2016 -
Juno restarts suspended CAR-T trial after FDA lifts clinical hold
The surprise reversal comes just days after the trial was stopped following three patient deaths.
By Ned Pagliarulo • July 12, 2016 -
Shire's dry eye drug wins long-awaited FDA approval
Xiidra is projected to enter the market as the first drug treating both signs and symptoms of dry eye disease.
By Edwin Lopez • July 12, 2016 -
EMA says benefits of Gilead's Zydelig outweigh risks
The European regulator had begun a review of the cancer drug four months ago after higher rates of adverse events, including patient deaths, were observed in clinical trials.
By Nicole Gray • July 11, 2016 -
FDA panel to review Humira, Enbrel biosimilars this week
Amgen and Novartis, respectively, are both aiming to wrest market share away from the two blockbuster biologics, although Amgen finds itself both pushing for and defending itself from biosim competition.
By Edwin Lopez • July 11, 2016 -
Gilead secures European approval for new hepatitis C drug
Epclusa is the first drug approved to treat all six genotypes of the liver disease.
By Nicole Gray • July 11, 2016 -
Facing major penalties, Theranos could be forced to change business
The blood-testing company acknowledged it might cease operations at both its California and Arizona labs if sanctions recently imposed by regulators are upheld.
By Ned Pagliarulo • July 11, 2016 -
Pfizer's leukemia drug approved by UK cost watchdog after previous rejection
Bosulif is the first treatment previously rejected by NICE to be reconsidered and approved for coverage.
By Nicole Gray • July 8, 2016 -
FDA staff backs Amgen biosim of AbbVie's Humira
An independent advisory panel is set to review Amgen's application early next week.
By Ned Pagliarulo • July 8, 2016 -
NHS England to cover PTC's Duchenne drug after access deal
PTC Therapeutics has been hit hard since the FDA said its application for U.S. approval of the drug was incomplete.
By Edwin Lopez • July 8, 2016 -
Theranos founder banned from blood-testing business
Health regulators also stripped a certification from the company's Newark, CA lab as part of the severe penalties levied on the company for testing violations.
By Ned Pagliarulo • July 8, 2016 -
FDA
Juno CAR-T trial halted by FDA after three patient deaths
The deaths occurred in a study evaluating the immunotherapy JCAR015 in patients with acute lymphoblastic leukemia.
By Ned Pagliarulo • July 7, 2016 -
Bial's Parkinson's drug wins approval in Europe
Ongentys is designed as an add-on therapy to levodopa, a common drug used to improve muscle control in Parkinson's patients.
By Nicole Gray • July 7, 2016 -
EMA: Member states will determine agency's new location
The Spanish and Italian governments are already lobbying to be the new seat of the European Union's top drug regulator.
By Edwin Lopez • July 7, 2016 -
Japanese regulators approve PCSK9 drug from Sanofi, Regeneron
But Praluent will face competition from Amgen's Repatha, which beat it to market in Japan by nearly six months.
By Nicole Gray • July 6, 2016 -
AstraZeneca, Genzyme sanctioned by UK group for marketing missteps
The Association of British Pharmaceutical Industry cited the companies separately for providing inaccurate information and making misleading claims.
By Edwin Lopez • July 6, 2016 -
Federal appeals court reaffirms biosimilar launch rules
The Supreme Court is considering whether to hear a related case on when biosimilar drugmakers must notify brand name companies of their intent to sell copy biologics.
By Ned Pagliarulo • July 5, 2016 -
Insys stages recovery as FDA approves liquid THC drug
Syndros, Insys' second-approved drug, is still awaiting DEA scheduling however.
By Edwin Lopez • July 5, 2016 -
UK cost agency knocks back Bristol-Myers' Opdivo in kidney cancer
In draft guidance, the watchdog raised concerns over the cancer immunotherapy's long term benefit in treating renal cell carcinoma.
By Ned Pagliarulo • July 5, 2016 -
Patent Office accelerates patent review for cancer drugs in pilot program
Under the program, the Patent Office hopes to make final decisions on patent applications for cancer therapies within 12 months.
By Nicole Gray • July 1, 2016 -
J&J, AbbVie eye new indication for cancer drug Imbruvica
A fourth breakthrough therapy designation from the FDA could set up the drug for an indication outside of blood cancers.
By Nicole Gray • July 1, 2016 -
Two more Chinese drugmakers run afoul of FDA inspections
Employees of one firm, Chongqing Lummy, were cited for turning back computer clocks to make it appear as if testing on APIs had been conducted months earlier.
By Nicole Gray • June 30, 2016
Previous
